Macuneos - Biophytis

Drug Profile

Macuneos - Biophytis

Alternative Names: BIO-201

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biophytis
  • Class Eye disorder therapies
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Age-related macular degeneration
  • Preclinical Dry age-related macular degeneration; Stargardt disease

Most Recent Events

  • 27 Oct 2017 Preclinical trials in Stargardt disease 1 in France (unspecified route) before October 2017
  • 04 Apr 2017 Biophytis plans the phase II MACA-INT trial for Age-related macular degeneration
  • 22 Mar 2017 Preclinical trials in Dry age-related macular degeneration in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top